Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial

Vol.:(0123456789) 1 3 Annals of Hematology https://doi.org/10.1007/s00277-021-04545-5 CORRECTION Correction to: Clinical benefit ofglasdegib pluslow‑dose cytarabine inpatients withde novo andsecondary acute myeloid leukemia: long‑term analysis ofaphase II randomized trial MichaelHeuser1· B.DouglasSmith2· WalterFiedler3· MikkaelA.Sekeres4· PauMontesinos5,6· BrianLeber7· AkilMerchant8· CristinaPapayannidis9· JoséA.Pérez‑Simón10· CarolineJ.Hoang11· ThomasO’Brien11· WeidongWendyMa11· MirjanaZeremski11· AshleighO’Connell11· GeoffreyChan11· JorgeE.Cortes12,13 © The Author(s) 2021 Correction to: Annals of Hematology https:// doi. org/ 10. 1007/ s0027702104465-4 Due to an oversight during the preparation of figures for manuscript submission, the numbers of patients at risk were omitted from the bottom of Fig.1, panel C. These have now been added along the x-axis to ensure that readers have the most complete information regarding the analysis shown. The original article has been corrected. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The original article can be found online at https:// doi. org/ 10. 1007/ s0027702104465-4. * Michael Heuser [email protected] 1 Department ofHematology, Hemostasis, Oncology andStem Cell Transplantation, Hannover Medical School, Carl-Neuberg-Str. 1, 30625Hannover, Germany 2 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA 3 Department ofHematology andOncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany 4 Division ofHematology, Sylvester Comprehensive Cancer Center, University ofMiami, Miami, FL, USA 5 Hospital Universitari I Politècnic La Fe, Valencia, Spain 6 CIBERONC, Instituto Carlos III, Madrid, Spain 7 Juravinski Hospital At Hamilton Health Sciences, Hamilton, ON, Canada 8 Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, LosAngeles, CA, USA 9 IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy 10 Hospital Universitario Virgen del Rocío, Instituto de Biomedicina (IbiS)/CSIC/CIBERONC), Universidad de Sevilla, Seville, Spain 11 Pfizer Inc, NewYork, NY, USA 12 University ofTexas MD Anderson Cancer Center, Houston, TX, USA 13 Present Address: Georgia Cancer Center, Augusta, GA, USA Annals of Hematology 1 3 Fig. 1 Kaplan–Meier plots of overall survival in the a overall population, b de novo AML subgroup, c secondary AML subgroup, and d overall population censoring for patients receiving follow-up HMAs. GLAS, glasdegib; mo, months; mOS, median overall survival + ++ ++ + + 38 37 32 26 23 19 18 16 16 14 14 14 14 10 9777755555444322222222222211110 18 16 11 11 9766655332222222211111111111111111111110 010 20 30 40 50 Survival time (months) 0.0 0.2 0.4 0.6 0.8 1.0 b d a Survival probability + Censored + Censored + Censored mOS (95% CI), mo GLAS + LDAC 6.6 (3.7–12.4) LDAC alone 4.3 (1.3–10.7) HR 0.720; 95% CI 0.395–1.312; p = 0.1398 1-year survival 2-year survival mOS (95% CI), mo (95% CI), % (95% CI), % GLAS + LDAC 8.3 (4.7–12.2) 39.4 (28.3–50.3) 19.0 (11.0–28.7) LDAC alone 4.3 (1.9–5.7) 8.4 (2.2–20.1) 2.8 (0.2–12.4) HR 0.495; 95% CI 0.325–0.752; p = 0.0004 mOS (95% CI), mo GLAS + LDAC 6.5 (3.5–8.8) LDAC alone 3.5 (1.8–4.9) HR 0.538; 95% CI 0.340–0.853; p = 0.0037 No. at risk GLAS + LDAC LDAC alone No. at risk GLAS + LDAC 78 38 72 32 67 23 57 21 50 19 45 14 44 12 41 9 37 8 35 6 30 6 30 3 29 3 25 2 24 2 21 2 21 2 20 2 20 2 17 2 15 2 15 1 15 1 15 1 14 1 12 1 12 1 9 1 8 1 8 1 8 1 8 1 8 1 8 1 8 1 6 1 5 1 5 1 5 1 5 1 4 1 4 1 4 1 4 0 211111 0 59 34 53 28 48 19 38 17 32 15 29 10 28 8 25 6 22 5 20 4 16 4 16 1 16 1 13 1 12 2 10 1 10 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 6 1 6 1 6 1 6 1 6 1 6 1 6 1 6 1 5 1 4 1 4 1 4 1 4 1 3 1 3 1 3 1 3 0 211111 0 Survival time (months) No. at risk GLAS + LDAC LDAC alone Survival time (months) No. at risk GLAS + LDAC LDAC alone LDAC alone 0 10 20 30 40 50 Survival time (months) 0.0 0.2 0.4 0.6 0.8 1.0 c Survival probability + Censored mOS (95% CI), mo GLAS + LDAC 9.1 (4.4–16.5) LDAC alone 4.1 (1.5–6.4) HR 0.287; 95% CI 0.151–0.548; p < 0.0001 + ++ + + + + ++ ++++ + + + + 0 10 20 30 40 50 0.0 0.2 0.4 0.6 0.8 1.0 Survival probability + + ++ + + 0 10 20 30 40 50 0.0 0.2 0.4 0.6 0.8 1.0 Survival probability ++++ + 40 35 35 31 27 26 26 25 21 21 16 16 15 15 15 14 14 13 13 12 10 10 10 10 10 88666666664333333332111110 20 16 12 10 10 7632110